B

Biome Australia Ltd
ASX:BIO

Watchlist Manager
Biome Australia Ltd
ASX:BIO
Watchlist
Price: 0.58 AUD 1.75% Market Closed
Market Cap: 127.1m AUD
Have any thoughts about
Biome Australia Ltd?
Write Note

Biome Australia Ltd
Net Issuance of Common Stock

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Biome Australia Ltd
Net Issuance of Common Stock Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Issuance of Common Stock CAGR 3Y CAGR 5Y CAGR 10Y
B
Biome Australia Ltd
ASX:BIO
Net Issuance of Common Stock
AU$642.4k
CAGR 3-Years
-38%
CAGR 5-Years
-27%
CAGR 10-Years
N/A
Bioxyne Ltd
ASX:BXN
Net Issuance of Common Stock
AU$1.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
McPherson's Ltd
ASX:MCP
Net Issuance of Common Stock
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Star Combo Pharma Ltd
ASX:S66
Net Issuance of Common Stock
AU$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Elixinol Wellness Ltd
ASX:EXL
Net Issuance of Common Stock
AU$2.3m
CAGR 3-Years
-58%
CAGR 5-Years
-44%
CAGR 10-Years
N/A
H
Hydration Pharmaceuticals Co Ltd
ASX:HPC
Net Issuance of Common Stock
$3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Biome Australia Ltd
Glance View

Market Cap
124.8m AUD
Industry
Consumer products

Biome Australia Ltd. engages in the development and marketing of live biotherapeutics and complementary medicines. The company is headquartered in Melbourne, Victoria. The company went IPO on 2021-11-30. The firm licenses, develops and markets evidence-based, complementary medicines, including nutraceuticals (food-based vitamins and weight management products) and live biotherapeutics (probiotics). The company markets and distributes clinically researched products developed in conjunction with its strategic partners. Its products include 22 products marketed under three brands, being Activated Probiotics, Activated Nutrients and Activated X Performance. These products are distributed through community pharmacies, independent health practitioners and online direct to consumer channels. The company offers biotherapeutic products to help prevent and support the management of various health concerns, including low mood and sleep, bone health, iron malabsorption, mild eczema and irritable bowel syndrome (IBS), through randomized double-blind placebo-controlled trials.

BIO Intrinsic Value
0.32 AUD
Overvaluation 44%
Intrinsic Value
Price
B

See Also

What is Biome Australia Ltd's Net Issuance of Common Stock?
Net Issuance of Common Stock
642.4k AUD

Based on the financial report for Jun 30, 2024, Biome Australia Ltd's Net Issuance of Common Stock amounts to 642.4k AUD.

What is Biome Australia Ltd's Net Issuance of Common Stock growth rate?
Net Issuance of Common Stock CAGR 5Y
-27%

Over the last year, the Net Issuance of Common Stock growth was 128 384%. The average annual Net Issuance of Common Stock growth rates for Biome Australia Ltd have been -38% over the past three years , -27% over the past five years .

Back to Top